Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : AZN save search
Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
Published: 2023-02-08 (Crawled : 15:20) - biospace.com/
FBIO | $0.7948 -4.81% 1.5M
|
Health Technology
|
| O: -12.84%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 2.6%
H: 0.0%
C: 0.0%
offering nasdaq biotech direct
Pulmonary Arterial Hypertension (PAH) Drugs Global Market 2022: Sector to Reach $9.4 Billion by 2027 at a CAGR of 5.29%
Published: 2023-02-03 (Crawled : 12:00) - prnewswire.com
JNJ | $164.18 0.48% 2.6M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
GSK | $36.445 0.76% 1.8M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
UTHR | $254.27 -0.54% 90K
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 0.47%
H: 0.0%
C: 0.0%
global hypertension market
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossExpects to Commence Phase 2a of CAReS During the First Quarter of 2023
Published: 2023-02-02 (Crawled : 15:20) - biospace.com/
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
ARTL A | $3.0 9.8K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
art27 treatment cares for trial art27.13 phase 2b
TEZSPIRE® approved for self-administration in the US with a new pre-filled pen
Published: 2023-02-02 (Crawled : 15:00) - biospace.com/
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
tezspire for approved
Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Published: 2023-02-02 (Crawled : 14:20) - globenewswire.com
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
ARTL A | $3.0 9.8K
|
Health Technology
|
| O: -1.27%
H: 0.0%
C: 0.0%
art27 treatment cares for trial art27.13 phase 2b
Flagship Pioneering Announces Appointment of Christian Schade as Growth Partner
Published: 2023-01-31 (Crawled : 12:20) - prnewswire.com
JNJ | $164.18 0.48% 2.6M
|
Health Technology
|
| O: -3.75%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -1.96%
H: 0.52%
C: 0.51%
growth
Global Gastrointestinal Therapeutics Market Report 2022: Sector to Reach $45.9 Billion by 2028 at a 3.8% CAGR
Published: 2023-01-30 (Crawled : 17:00) - prnewswire.com
TAK | $16.155 1.48% 1.2M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: 0.0%
PFE | $43.995 0.93% 7.9M
|
Health Technology
|
| O: -0.79%
H: 0.0%
C: 0.0%
JNJ | $164.18 0.48% 2.6M
|
Health Technology
|
| O: -0.26%
H: 0.0%
C: 0.0%
ABT | $110.32 -1.49% 1.5M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 1.45%
H: 0.0%
C: 0.0%
global report gastrointestinal therapeutics market
TROPION-Lung07 Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan in Combination with Pembrolizumab in Patients with Previously Untreated Metastatic Non-Small Cell Lung Cancer
Published: 2023-01-30 (Crawled : 14:00) - biospace.com/
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 1.45%
H: 0.0%
C: 0.0%
lung trial cancer initiated
GERD market size to increase by USD 908.49 million; North America to account for 38% of market growth - Technavio
Published: 2023-01-25 (Crawled : 03:00) - prnewswire.com
GSK | $36.445 0.76% 1.8M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
ABT | $110.32 -1.49% 1.5M
|
Health Technology
|
| O: -2.56%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -0.2%
H: 0.0%
C: 0.0%
america for growth market
AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.
Published: 2023-01-23 (Crawled : 13:00) - biospace.com/
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -1.28%
H: 0.57%
C: -1.6%
acquire
Worldwide Monoclonal Antibodies Industry to 2033 - Rising mAb Therapy Applications for Targeted Therapies Drives Growth
Published: 2023-01-18 (Crawled : 18:00) - prnewswire.com
VTRS | $12.025 -0.7% 1.6M
|
Health Technology
|
| O: -0.17%
H: 0.25%
C: -2.96%
TMO | $582.8 -0.06% 460K
|
Health Technology
|
| O: 0.56%
H: 0.97%
C: -1.87%
NVO | $139.75 0.12% 720K
|
Health Technology
|
| O: 0.57%
H: 0.84%
C: -0.01%
NVS | $87.315 1.13% 1.1M
|
Health Technology
|
| O: 0.08%
H: 0.01%
C: -1.16%
JNJ | $164.18 0.48% 2.6M
|
Health Technology
|
| O: -1.47%
H: 0.0%
C: 0.0%
GSK | $36.445 0.76% 1.8M
|
Health Technology
|
| O: -0.03%
H: 0.17%
C: -1.01%
LLY M | $341.98 0.68% 990K
|
Health Technology
|
| O: -1.13%
H: 0.0%
C: 0.0%
ABT | $110.32 -1.49% 1.5M
|
Health Technology
|
| O: -0.16%
H: 0.33%
C: -1.5%
SNY | $47.66 1.47% 1M
|
Health Technology
|
| O: -0.14%
H: 0.0%
C: 0.0%
BIIB A | $287.96 -1.19% 240K
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 1.36%
H: 0.33%
C: -1.13%
AMGN | $241.32 -1.1% 1.1M
|
Health Technology
|
| O: 0.0%
H: 0.41%
C: -1.87%
for therapy growth
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
Published: 2023-01-18 (Crawled : 15:00) - globenewswire.com
HCM | $18.26 -0.6% 37K
|
Health Technology
|
| O: 1.32%
H: 4.49%
C: 1.01%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 1.36%
H: 0.33%
C: -1.13%
orpathys drug for agreement china
Press release Biocartis Group NV: BIOCARTIS MEETS 2022 KEY OBJECTIVES
Published: 2023-01-17 (Crawled : 17:00) - globenewswire.com
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 0.86%
H: 0.03%
C: -1.23%
group
The Worldwide Lysosomal Disease Treatment Industry is Expected to Reach $11 Billion by 2028
Published: 2023-01-13 (Crawled : 13:00) - prnewswire.com
TAK | $16.155 1.48% 1.2M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: 0.0%
PFE | $43.995 0.93% 7.9M
|
Health Technology
|
| O: 1.08%
H: 0.0%
C: 0.0%
NVS | $87.315 1.13% 1.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
JNJ | $164.18 0.48% 2.6M
|
Health Technology
|
| O: -0.39%
H: 0.0%
C: 0.0%
LLY M | $341.98 0.68% 990K
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
SNY | $47.66 1.47% 1M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
BMRN | $110.94 -0.33% 400K
|
Health Technology
|
| O: 2.13%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
treatment disease expected
Global Head And Neck Cancer Therapeutics Market Report 2022: Sector to Reach $2.5 Billion by 2028 at a 12.3% CAGR
Published: 2023-01-12 (Crawled : 22:00) - prnewswire.com
TAK | $16.155 1.48% 1.2M
|
Health Technology
|
| O: 0.96%
H: 0.0%
C: 0.0%
LLY M | $341.98 0.68% 990K
|
Health Technology
|
| O: 0.4%
H: 0.0%
C: 0.0%
SNY | $47.66 1.47% 1M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 1.7%
H: 0.0%
C: 0.0%
global report therapeutics cancer market
Global Nasal Vaccines Markets and Pipeline Analysis Research Report 2022: A Major Game Changer in Blocking the Transmission of Diseases Such as COVID-19
Published: 2023-01-10 (Crawled : 21:00) - prnewswire.com
AZNCF | $128.7 0
|
Health Technology
|
| O: -1.28%
H: 0.0%
C: -0.82%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -0.33%
H: 0.13%
C: -1.28%
covid-19 research global report
Immune Checkpoint Inhibitors Market Predicted to Reach USD 155.1 Billion, Globally, by 2031 at 16.1% CAGR: Allied Market Research
Published: 2023-01-09 (Crawled : 10:00) - prnewswire.com
GSK | $36.445 0.76% 1.8M
|
Health Technology
|
| O: 1.76%
H: 0.0%
C: 0.0%
LLY M | $341.98 0.68% 990K
|
Health Technology
|
| O: 1.12%
H: 0.27%
C: -3.89%
SNY | $47.66 1.47% 1M
|
Health Technology
|
| O: 1.82%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: 1.67%
H: 0.86%
C: -0.21%
research market
Tempus Announces Prospective Study for Biomarker Discovery in Small Cell Lung Cancer
Published: 2023-01-05 (Crawled : 16:00) - biospace.com/
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
lung for biomarker cancer study
Genomic Vision announces successful beta testing of FiberSmart®
Published: 2023-01-05 (Crawled : 07:00) - globenewswire.com
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
fibersmart genomic
Global Type 2 Diabetes Treatment Market Outlook Report 2022-2023 & 2027: Patent Cliff, Oral Antidiabetics, and Growing Focus on Accessibility and Affordability of Medicine Bolsters Growth
Published: 2023-01-04 (Crawled : 23:00) - prnewswire.com
NVS | $87.315 1.13% 1.1M
|
Health Technology
|
| O: -0.84%
H: 0.0%
C: 0.0%
JNJ | $164.18 0.48% 2.6M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
SNY | $47.66 1.47% 1M
|
Health Technology
|
| O: -3.07%
H: 0.0%
C: 0.0%
AZN | $64.645 0.55% 3M
|
Health Technology
|
| O: -2.09%
H: 0.0%
C: 0.0%
treatment patent global report growing diabetes growth market
Gainers vs Losers
| 54% | 46% |
Top 10 Gainers
DGLY | $5.43 1722.15% 160K
|
Electronic Technology
CELZ | $1.115 115.54% 120M
|
AVRO | $1.78 104.01% 11M
|
Health Technology
GFAI | $0.4936 44.54% 62M
|
WETG | $0.551 34.39% 13M
|
KPRX | $6.11 34.29% 15M
|
Manufacturing
PRFX | $0.65 30.0% 13M
|
Health Technology
BBLG | $0.3799 20.76% 740K
|
n/a
NEWR A | $77.25 19.62% 2.7M
|
Technology Services
THCH | $4.99 18.81% 560K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.